Clinical Trial

Pulmonary Rehabilitation in Advanced Non-small Cell Lung Cancer Patients

Recruiting
View on ClinicalTrials.gov →
Summary
Lung cancer (LC) is usually diagnosed in advanced stages and continues to be the leading cause of cancer related deaths worldwide. Cancer cachexia are frequent among patients with LC affecting up to 80% of patients with advanced stage disease, and it has been related with higher risk of complications, length of hospital stay, and worst overall survival. During cancer cachexia, both muscle and fat mass can be wasted, however, the loss of muscle mass has been associated to higher treatment related toxicity, loss of functional status, shorter progression free survival and overall survival in different types of cancer under various treatments. Hence, preservation of muscle mass and function should be an important focus of the multidisciplinary treatment of patients with LC. Pulmonary rehabilitation (PR) has been known to improve pulmonary function, reduce fatigue and improve exercise tolerance in patients with LC undergoing curative surgery. However, few studies have focused on the efficacy of PR on patients with advanced cancer undergoing palliative care with chemotherapy or targeted therapies.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2016-11-28; most recent amendment 2026-04-06.
Trial Details
NCT Number NCT02978521
Lead Sponsor Instituto Nacional de Cancerologia de Mexico
Conditions Pulmonary Rehabilitation, Sarcopenia, Quality of Life
Enrollment 94 participants
Start Date 2016-08-05
Primary Completion 2026-12-05 (estimated)
Study Completion 2027-12-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-08